Up 25% in 1 Month, Is This Stock a Buy?

Key Points Recursion Pharmaceuticals' recent momentum is hard to explain. The company could soar even more if it makes strong clinical progress. Despite its innovative approach, the biotech looks risky. 10 stocks we like better than Recursion Pharmaceuticals › Many leading companies focused on artificial intelligence (AI) have seen their shares soar as they profit from the tailwind this market is currently experiencing. Perhaps a good way to cash in on this is to invest in smaller, under-the-rada ...